Alder BioPharmaceuticals® to Present at the 2018 Bank of America Merrill Lynch Health Care Conference
07 mai 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., May 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2018 Financial and Operating Results
30 avr. 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Appoints Jeremy Green to its Board of Directors
26 avr. 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 26, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic...
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
25 avr. 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 25, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine
24 avr. 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
- Data presented at AAN Annual Meeting demonstrate eptinezumab further reduces migraine risk following the third and fourth quarterly infusions - More than 50% of patients achieved a 75% reduction or...
Alder BioPharmaceuticals® Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer
23 avr. 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 23, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc., (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for Eptinezumab at the 70th Annual American Academy of Neurology Meeting
18 avr. 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 18, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer
16 avr. 2018 08h30 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 16, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic...
Alder BioPharmaceuticals® Appoints Paul B. Cleveland as Interim President and Chief Executive Officer
20 mars 2018 16h05 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., March 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at 38th Annual Cowen & Co. Health Care Conference
05 mars 2018 16h05 HE
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., March 05, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...